Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Nivolumab Market Valued at Present and by 2029?

The market size for nivolumab has seen a swift expansion in the past few years. It is projected to escalate from $1.69 billion in 2024 to $1.92 billion in 2025 with a compound annual growth rate (CAGR) of 13.7%. The growth observed in the historical period can be credited to advancements in immunotherapy, rising incidences of cancer, successful clinical trials, and regulatory approvals.

Within the ensuing years, the nivolumab market size is projected to experience swift expansion, reaching “$3.16 billion in 2029 at a compound annual growth rate (CAGR) of 13.3%.” The anticipated growth within the forecast period is as a result of developments in personalized medicine, new indications, worldwide access to cancer treatment, and advancement in combination therapies. Prominent trends during the forecast period entail biomarker-driven treatment, neoantigen vaccines, improved immunotherapy routines, and long-term follow-up research.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13012&type=smp

#What Drivers Are Influencing Growth In The Nivolumab Market?

The nivolumab market’s expansion is anticipated to be spurred by the increasing incidence of cancer. Cancer involves a group of diseases that can form in virtually any organ or tissue of the body when abnormal cells multiply beyond control, exceed their ordinary boundaries and either metastasize to other organs or invade surrounding body parts. Nivolumab is a critical tool used for the management and treatment of various cancer types by preventing cancer cells from weakening the immune system, thereby enabling the immune system to combat and eliminate the cancer cells. For example, the Australian Institute of Health and Welfare disclosed in July 2024, that the number of diagnosed cancer cases in Australia escalated from 156,781 in 2021 to 160,570 in 2022, depicting a surge of 3,789 cases within a year. Consequently, the escalating incidence of cancer is fuelling the expansion of the nivolumab market.

The nivolumab market covered in this report is segmented –

1) By Type: Injection 4mL, Injection 10mL

2) By Route Of Administration: Intravenous, Other Routes Of Administration

3) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications

4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Injection 4mL: Single-Dose Vial, Multi-Dose Vial

2) By Injection 10mL: Single-Dose Vial, Multi-Dose Vial

What Are The Leading Trends And Opportunities In The Nivolumab Sector?

Prominent corporations in the nivolumab sphere are concentrating on the creation of inventive medications to fulfil their customer needs and preserve their marketplace standing. The invention of new pharmaceuticals can enhance the results of treatments for patients suffering from a variety of illnesses. For example, Bristol-Myers Squibb Co., an American pharmaceutical enterprise chiefly devoted to cancer, cardiovascular, immunology, and fibrotic therapeutic ventures, revealed in May 2022 that the U.S. Food and Drug Administration (FDA) had given the green light to two nivolumab-centred regimens. These include the combination of Nivolumab with fluoropyrimidine and platinum-based chemotherapy and the pairing of Nivolumab and Yervoy (ipilimumab). These regimens have been approved for the initial treatment of adult patients with unremovable advanced or metastatic esophageal squamous cell carcinoma (ESCC) irrespective of their PD-L1 status.

Which Companies Play A Key Role In The Development Of The Nivolumab Market?

Major companies operating in the nivolumab market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Nippon Kayaku Co. Ltd., Luye Pharma AG, Genentech Inc., Taiho Pharmaceutical Co. Ltd., SymBio Pharmaceuticals Ltd., Xbrane Biopharma AB, NeuClone Therapeutics Inc.

https://www.thebusinessresearchcompany.com/report/nivolumab-global-market-report

What Are The Key Regional Developments Shaping The Nivolumab Market?

North America was the largest region in the nivolumab market in 2024. The regions covered in nivolumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13012&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model